This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Haperen, V. W. T. R. Articles by Peters, G. J. Search for Related Content PubMed PubMed Citation Articles by van Haperen, V. W. T. R. Articles by Peters, G. J.

Development and Molecular Characterization of a 2',2'-Difluorodeoxycytidine-resistant Variant of the Human Ovarian Carcinoma Cell Line A2780¹

Departments of Oncology [V. W. T. R. v. H., G. V., E. B., J. B. V., H. M. P., G. J. P.] and Human Genetics [M. H.], Free University Hospital, P. O. Box 7057, 1007 MB Amsterdam, and Department of Haematology, University Hospital, Leiden, the Netherlands [A. P. A. S], and Department of Veterinarian Medical Chemistry, Swedish University of Agricultural Sciences, The Biomedical Centre, Uppsala, Sweden [S. E.]

2',2'-Difluorodeoxycytidine (gemcitabine, dFdCyd) is a deoxycytidine analogue with promising antitumor activity. In order to be active it must be phosphorylated by deoxycytidine kinase (dCK). We induced resistance to dFdCyd in the human ovarian carcinoma cell line A2780 by exposure to increasing concentrations of dFdCyd. The IC₅₀, defined as the concentration of dFdCyd causing 50% growth inhibition, at 72 h exposure increased from 0.6 nM dFdCyd in A2780 to 92 µM in the resistant variant, named AG6000. Although the resistant cell line is routinely cultured in 6 µM dFdCyd, the resistant phenotype can be maintained for at least 10 passages without dFdCyd. AG6000 is cross-resistant to other drugs which require activation by dCK, such as 1-ß-D-arabinofuranosylcytosine, 5-aza-2'-deoxycytidine, and 2-chlorodeoxyadenosine. There was no specific dCK activity in extracts from AG6000 cells. Western blot analysis using a polyclonal anti-dCK antibody did not reveal any dCK protein in AG6000 cell extracts. Reverse-transcribed and PCR-amplified mRNA, using specific dCK primers, demonstrated that AG6000 expressed a normal length amplicon of 701 base pairs, besides an aberrant amplicon of 500 base pairs. Chromosome spreads from the cell lines showed no major differences between A2780 and AG6000. The latter cell line was also cross-resistant to 2',2'-difluorodeoxyurdine, the deamination product of dFdCyd. Additionally, cross-resistance to the multidrug resistance drugs doxorubicin and vincristine was observed. This was not associated with the induction of P-glycoprotein, as determined by the RNase protection assay. Injection of AG6000 cells s.c. into nude mice demonstrated that the cell line had retained its tumorigenicity; AG6000 xenografts were not sensitive to dFdCyd treatment, in contrast to the parental A2780 tumors. No dFdCyd triphosphate accumulation was found in the resistant tumors, in contrast to the parental A2780 tumors. These results indicate that the dFdCyd resistance phenotype is stable, and mainly due to dCK deficiency.

¹ This study was supported by the ICRETT 565 award (V. W. T. R. v. H.) from the International Union Against Cancer, Geneva, and Grant IKA-VU 90–19 from the Dutch Cancer Society, Amsterdam. S. E. is supported by the Swedish National Board for Industrial and Technical Development and the Swedish Medical Research Council.

² To whom requests for reprints should be addressed.

Received 3/ 2/94. Accepted 6/ 1/94.

This article has been cited by other articles:

				L. H. Reddy, H. Khoury, A. Paci, A. Deroussent, H. Ferreira, C. Dubernet, X. Decleves, M. Besnard, H. Chacun, S. Lepetre-Mouelhi, et al. Squalenoylation Favorably Modifies the in Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice Drug Metab. Dispos., August 1, 2008; 36(8): 1570 - 1577. [Abstract] [Full Text] [PDF]

				S. A. Veltkamp, J. H. Beijnen, and J. H.M. Schellens Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy Oncologist, March 1, 2008; 13(3): 261 - 276. [Abstract] [Full Text] [PDF]

				T. Oguri, H. Achiwa, S. Sato, Y. Bessho, Y. Takano, M. Miyazaki, H. Muramatsu, H. Maeda, T. Niimi, and R. Ueda The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol. Cancer Ther., July 1, 2006; 5(7): 1800 - 1806. [Abstract] [Full Text] [PDF]

				I Hubeek, G J Peters, A J F Broekhuizen, I Talianidis, J Sigmond, B E S Gibson, U Creutzig, G Giaccone, and G J L Kaspers Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours J. Clin. Pathol., July 1, 2005; 58(7): 695 - 699. [Abstract] [Full Text] [PDF]

				L. P. Jordheim, E. Cros, M.-H. Gouy, C. M. Galmarini, S. Peyrottes, J. Mackey, C. Perigaud, and C. Dumontet Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line: Reversion of In vitro Resistance by a Mononucleotide Prodrug Clin. Cancer Res., August 15, 2004; 10(16): 5614 - 5621. [Abstract] [Full Text] [PDF]

				J. R. Kroep, W. J. P. Loves, C. L. van der Wilt, E. Alvarez, I. Talianidis, E. Boven, B. J. M. Braakhuis, C. J. van Groeningen, H. M. Pinedo, and G. J. Peters Pretreatment Deoxycytidine Kinase Levels Predict in Vivo Gemcitabine Sensitivity Mol. Cancer Ther., April 1, 2002; 1(6): 371 - 376. [Abstract] [Full Text] [PDF]

				M. J. T. Veuger, M. H. M. Heemskerk, M. W. Honders, R. Willemze, and R. M. Y. Barge Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells Blood, February 15, 2002; 99(4): 1373 - 1380. [Abstract] [Full Text] [PDF]

				C. L. van der Wilt, H. H. J. Backus, K. Smid, L. Comijn, G. Veerman, D. Wouters, D. A. Voorn, D. G. Priest, M. A. Bunni, F. Mitchell, et al. Modulation of Both Endogenous Folates and Thymidine Enhance the Therapeutic Efficacy of Thymidylate Synthase Inhibitors Cancer Res., May 1, 2001; 61(9): 3675 - 3681. [Abstract] [Full Text]

				M. J. T. Veuger, M. W. Honders, J. E. Landegent, R. Willemze, and R. M. Y. Barge High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia Blood, August 15, 2000; 96(4): 1517 - 1524. [Abstract] [Full Text] [PDF]

				Y.-G. Goan, B. Zhou, E. Hu, S. Mi, and Y. Yen Overexpression of Ribonucleotide Reductase as a Mechanism of Resistance to 2,2-Difluorodeoxycytidine in the Human KB Cancer Cell Line Cancer Res., September 1, 1999; 59(17): 4204 - 4207. [Abstract] [Full Text] [PDF]

				L. Crino, A. M. Mosconi, G. Scagliotti, G. Selvaggi, S. Novello, M. Rinaldi, M. Della Giulia, C. Gridelli, A. Rossi, C. Calandri, et al. Gemcitabine as Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Phase II Trial J. Clin. Oncol., July 1, 1999; 17(7): 2081 - 2081. [Abstract] [Full Text] [PDF]

				P. Hatzis, A. S. Al-Madhoon, M. Jullig, T. G. Petrakis, S. Eriksson, and I. Talianidis The Intracellular Localization of Deoxycytidine Kinase J. Biol. Chem., November 13, 1998; 273(46): 30239 - 30243. [Abstract] [Full Text] [PDF]